BaseSpace
Correlation Engine 2.0
Import Your Data
QuickView

FAQ

More QuickView FAQs

Back to top
Clear Search sequence regions
(e.g. rs3825942, KLK3, Fatty acid metabolic process, Inflammatory disorder, Intestine)
Bookmark Forward

QuickView for regulation of peroxisome proliferator activated receptor signaling pathway (biogroup)


Body Atlas

Most Correlated Tissues

  1. Parietal lobe
  2. Breast tissue
  3. Pons
  4. Occipital lobe
  5. Thalamus
Explore Body Atlas Results

Disease Atlas

Most Correlated Diseases

  1. Pyloric ulcer
  2. Vesicular stomatitis Indiana virus disease
  3. Peritoneal foreign body
  4. Placental insufficiency
  5. Contact dermatitis
Explore Disease Atlas Results

Pharmaco Atlas

Most Correlated Compounds

  1. GSK-J1
  2. flavopiridol
  3. WYE 125132
  4. NVP-AEW541
  5. ((3Z)-N-(3-chlorophenyl)-3-((3,5-dimethyl-4-((4-methylpiperazin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-N-methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonamide)
Explore Pharmaco Atlas Results

Knockdown Atlas

Most Correlated Gene Perturbations

  1. MIR192
  2. SMNDC1
  3. TMPRSS2
  4. PPP2R2C
  5. ACLY
Explore Knockdown Atlas Results

Curated Studies

Most Correlated Studies

  1. L1000 CMAP - Breast carcinoma BT20 cells treated with small molecule perturbagens
  2. L1000 CMAP - Bone marrow CD34 cells treated with small molecule perturbagens
  3. L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (1 of 4)
  4. L1000 CMAP - Prostate cancer LNCAP cells treated with small molecule perturbagens
  5. L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (2 of 4)
Explore Curated Studies Results

Literature

Most Relevant Literature

There were no matches for regulation of peroxisome proliferator activated receptor signaling pathway
Explore Literature Results

Clinical Trials

Most Relevant Clinical Trials

  1. Metabolic Signalling in Muscle- and Adipose-tissue Following Insulin Withdrawal and Growth Hormone I…
  2. Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor …
  3. Changes After Angiotensin Converting Enzyme (ACE) Inhibitor Replacement by Angiotensin II Receptor T…
  4. PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS
  5. A Case Control Study of Resveratrol Effects in Coronary Artery Disease Patients With Metabolic Syndr…
Explore Clinical Trials Results
  • Copyright © 2024 Illumina Inc. All rights reserved.